KYNTRA BIO, INC. quarterly report, Q2 FY2018

Business context and reporting period

This is FibroGen, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018; the supplied company metadata names a different company. FibroGen is a clinical-stage biopharmaceutical company. Its lead candidate, roxadustat, was in Phase 3 development for anemia in chronic kidney disease (CKD) and myelodysplastic syndromes (MDS); pamrevlumab was in Phase 2 development for idiopathic pulmonary fibrosis (IPF), pancreatic cancer and Duchenne muscular dystrophy (DMD). Substantially all revenue came from collaborations with Astellas and AstraZeneca; the company reported no product-sales revenue.

Financial performance and position

Amounts below are in millions of dollars except per-share data. Prior-period revenue figures were recast following adoption of ASC 606.

Quarterly operating loss was about 53% of revenue; the six-month operating loss was about 84% of revenue. The filing does not present a conventional gross margin measure. Quarterly revenue rose 45%, primarily because $14.9 million of a Japan regulatory milestone was recognized; six-month revenue rose 27%. Despite higher revenue, six-month net loss increased about $2.3 million year over year as operating expenses grew faster.

• Research and development expense was $52.1 million in Q2 and $109.1 million for the six months, up 11% and 16%, respectively. Management cited increased pamrevlumab drug-substance manufacturing, employee costs and stock-based compensation, partly offset by lower clinical-trial costs.
• General and administrative expense was $15.1 million in Q2 and $30.6 million for the six months, up 12% and 23%, respectively, primarily reflecting higher stock-based compensation, headcount and facility costs.
• Operating cash use was $66.9 million for the six months, versus $46.9 million in the comparable 2017 period. Investing activities provided $29.9 million and financing activities provided $7.1 million. Cash and cash equivalents fell $29.9 million during the half.
• At June 30, cash and cash equivalents were $643.8 million; short- and long-term investments totaled $38.7 million; accounts receivable was $30.2 million. Management reported these three items together at $712.7 million.
• Total assets were $869.9 million and total liabilities $355.1 million. Long-term lease-financing obligations were $97.5 million; product-development obligations were $17.0 million. The filing does not identify conventional borrowings as a material liability.
• Accumulated deficit was $694.2 million. Common shares outstanding were 84.2 million at June 30 and 84,333,402 at July 31, 2018.

Material changes and unusual items

• The Q2 revenue increase included a $15.0 million Japan NDA-submission milestone with Astellas: $14.9 million was recognized as revenue after management judged the milestone probable, including $14.3 million classified as license revenue. This recognition included a true-up relating to prior periods.
• FibroGen delivered roxadustat active pharmaceutical ingredient to Astellas for commercial-scale manufacturing validation. The associated $20.9 million was recorded as deferred revenue because Astellas’ right to use the material was limited at quarter-end. The related receivable contributed to the increase in accounts receivable.
• ASC 606 was adopted retrospectively on January 1, 2018, changing the timing and classification of collaboration revenue, including milestone and co-development consideration. The company recast prior-period comparisons; adoption had no impact on previously reported cash flows.
• Stock-based compensation was $24.1 million for the first half, versus $18.0 million a year earlier. The company received $17.3 million from common-stock issuance, principally option exercises and employee stock purchases, and paid $10.0 million in payroll taxes on restricted stock unit releases.

Outlook, commentary and risks

• Management said existing cash, investments and receivables were expected to fund anticipated cash requirements for at least the next 12 months. It also expected continued losses and substantial funding needs; future spending and financing requirements could change.
• For U.S. roxadustat CKD Phase 3 studies, enrollment was complete. Management expected the last patient visit in Q3 2018, topline results in Q4 2018 and pooled safety data before a U.S. NDA submission in the first half of 2019. A China CKD approval decision was anticipated by year-end 2018; Astellas expected to submit a Japan NDA for dialysis-dependent CKD in 2018.
• FibroGen expected to begin Phase 3 trials of pamrevlumab for IPF and pancreatic cancer in early 2019. The planned pancreatic-cancer study was approximately 260 patients; any accelerated-approval discussion would depend on interim resection-rate results, with overall survival the primary endpoint.
• Key risks include clinical-trial efficacy and safety outcomes, regulatory delays or rejection, manufacturing capacity and quality, dependence on Astellas and AstraZeneca, competition, reimbursement and pricing uncertainty, and China regulatory, operational and intellectual-property risks. Management noted possible roxadustat/statin interactions and that larger Phase 3 studies could reveal safety issues not seen in earlier trials.
• No material legal proceedings were reported. Management concluded disclosure controls were effective at the reasonable-assurance level as of June 30, 2018; no material change in internal control over financial reporting was reported for the quarter.

Important facts for investors to verify

• Confirm the filing identity: the document is FibroGen, Inc.’s 2018 Q2 10-Q, not a filing for Kyntra Bio, Inc.
• Track whether the Japan NDA-submission milestone is achieved and billed, and how the related $15.0 million consideration and prior-period true-up affect revenue and receivables.
• Monitor collection and revenue recognition for the $20.9 million Astellas API transfer, which was deferred at June 30, and the company’s broader deferred-revenue balance of $175.3 million.
• Compare subsequent clinical readouts and regulatory submissions with the company’s stated roxadustat and pamrevlumab timelines, including pivotal safety data.
• Assess cash burn against management’s 12-month liquidity statement and monitor collaboration funding, manufacturing readiness, and potential additional financing or dilution.